Purchase this article for $4.95

Publication: FDA Consumer
Publication Date: 01-MAR-07
Delivery: Immediate Online Access
Author:

Article Excerpt
In November 2006, the FDA expanded the approved use of Herceptin (trastuzumab), a biological cancer drug. This new indication is for Herceptin, in combination with other cancer drugs, as treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy).

Herceptin is a targeted therapy against the HER2 protein on cancer cells. When an excessive amount of HER2 protein is present, it causes cancer cells to grow more...

NOTE: All illustrations and photos have been removed from this article.



More articles from FDA Consumer
Warnings for makers of compounded pain products., 01-MAR-07
How the FDA works to keep produce safe, 01-MAR-07
Animal cloning and food safety., 01-MAR-07

Looking for additional articles?
Click here to search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Click here to search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.